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https://doi.org/10.1016/j.celrep.2020.108533SUMMARYAltering ubiquitination by disruption of deubiquitinating enzymes (DUBs) affects hematopoietic stem cell
(HSC) maintenance. However, comprehensive knowledge of DUB function during hematopoiesis in vivo is
lacking. Here, we systematically inactivate DUBs in mouse hematopoietic progenitors using in vivo small
hairpin RNA (shRNA) screens. We find that multiple DUBs may be individually required for hematopoiesis
and identify ubiquitin-specific protease 15 (USP15) as essential for HSC maintenance in vitro and in trans-
plantations and Usp15 knockout (KO) mice in vivo. USP15 is highly expressed in human hematopoietic tis-
sues and leukemias. USP15 depletion in murine progenitors and leukemia cells impairs in vitro expansion
and increases genotoxic stress. In leukemia cells, USP15 interacts with and stabilizes FUS (fused in sar-
coma), a known DNA repair factor, directly linking USP15 to the DNA damage response (DDR). Our study un-
derscores the importance of DUBs in preserving normal hematopoiesis and uncovers USP15 as a critical
DUB in safeguarding genome integrity in HSCs and leukemia cells.INTRODUCTION
Hematopoietic stem cells (HSCs) have the unique properties
of self-renewal and multilineage potential, giving rise to
daughter stem cells and committed progenitors, thereby
achieving lifelong hematopoiesis. This is accomplished by
maintenance of a homeostatic balance among HSC quies-
cence, self-renewal, and differentiation (de Haan and Lazare,
2018; Laurenti and Göttgens, 2018; Morrison and Spradling,
2008). Perturbation of this balance and replication stress
can cause stem cell failure or transform normal HSCs and pro-
genitors into disease-initiating leukemic stem cells (LSCs)
(Flach et al., 2014). Understanding HSC and bone marrow
(BM) homeostasis is therefore essential for understanding
mechanisms controlling diseases and ultimately targeting
LSCs (Warr et al., 2011).Ce
This is an open access article undThe 76-amino-acid molecule ubiquitin is conjugated to pro-
teins as a monomer (mono-ubiquitination) or in the form of ubiq-
uitin chains (poly-ubiquitination) through the sequential action of
E1, E2, and E3 enzymes (Yau and Rape, 2016). Deubiquitinating
enzymes (DUBs; also referred to as deubiquitylating enzymes or
deubiquitinases) reverse substrate ubiquitination, thereby criti-
cally regulating ubiquitin-mediated signaling pathways,
including protein homeostasis and DNA repair (Mevissen and
Komander, 2017). Consequently, deregulation of DUBs is impli-
cated in human pathologies, such as cancer and neurodegener-
ative, hematological, and infectious diseases (Heideker and
Wertz, 2015).
The human genome encodes 100 DUBs, which are grouped
into seven families based on structural properties (Haahr et al.,
2018; Kwasna et al., 2018; Mevissen and Komander, 2017).
We reported that ubiquitin-specific protease 3 (USP3) protectsll Reports 33, 108533, December 29, 2020 ª 2020 The Author(s). 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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OPEN ACCESSmouse HSC function throughmodulation of the ubiquitin-depen-
dent DNA damage response (DDR), a critical genome mainte-
nance pathway (Lancini et al., 2014). This is in line with a proper
DDR being crucial to HSC function (Bakker and Passegué, 2013;
Biechonski et al., 2017). Numerous DUBs control ubiquitin-
dependent DDR (Citterio, 2015; Lukas et al., 2011; Nishi et al.,
2014; Schwertman et al., 2016), and DUB deregulation contrib-
utes to altered HSC homeostasis and human blood diseases
(Adorno et al., 2013; Dey et al., 2012; Gu et al., 2016).
Functional analysis of HSCs within their physiological environ-
ment is more likely to result in findingmodulators potentially rele-
vant in disease (Morrison and Spradling, 2008; Schepers et al.,
2015). Unbiased, functional genomic approaches by short
hairpin RNAs (shRNAs) have demonstrated the power of forward
RNAi screens in dissecting functional aspects of both normal
(Cellot et al., 2013; Galeev et al., 2016) and leukemic HSCs
(Zuber et al., 2011). Using lentiviral-based libraries (Gargiulo
et al., 2014; Serresi et al., 2018), pooled in vivo screening ap-
proaches in early murine hematopoietic precursors led to the
identification of critical factors limiting normal HSC self-renewal
(Wang et al., 2012), as well as of determinants of malignant he-
matopoiesis (Miller et al., 2013; Puram et al., 2016).
While recent gene-centric approaches connected DUBs to
HSC maintenance (Citterio, 2015), a comprehensive under-
standing of DUB biological functions in hematopoiesis and leu-
kemia is missing. DUBs are poorly represented in in vivo screens
(Wang et al., 2012), and in vitro functional approaches for DUBs
in cancer cell lines were hypothesis driven (Nishi et al., 2014). In
this study, we individually depleted all DUB genes using in vivo
RNAi screens in mouse hematopoietic precursors, with the aim
of ranking the most relevant DUBs required for normal and ma-
lignant hematopoiesis. We uncovered multiple DUBs as putative
regulators of hematopoietic precursors activity and highlighted
USP15 as a determinant of hematopoiesis in vivo and its role in
preserving genome integrity, with potential implications for
combinatorial treatments in leukemia.
RESULTS
In Vivo RNAi Screens for DUBs Identify DUB Regulators
of HSPC Activity
To identify DUB determinants of mouse HSC activity, we per-
formed pooled in vivo RNAi screens using adult murine hemato-
poietic stem and progenitor cells (HSPCs, mHSPCs) in a BM
transplantation setting (Figure 1A). We generated a custom
pool of 508 lentiviral shRNAs vectors potentially targeting all an-
notated mouse orthologs of human DUBs (100) (Mevissen and
Komander, 2017). This primary library contained three to six
shRNA vectors per gene, selected from the shRNA library devel-
oped by the RNAi Consortium (TRC) at the Broad Institute (Open
Biosystem) (Tables S1 and S2). Since statistical representation
of shRNA libraries is critical for success in in vivo screening,
we used the full library in a primary screen and divided the library
into two sub-pools (DUB1 and DUB2 sub-libraries) used in sec-
ondary screens (Figure 1B). To perform qualitative controls, we
included in each library shRNAs targeting known HSCs regula-
tors as positive controls (Park et al., 2003; Vasanthakumar
et al., 2016; Wang et al., 2012).2 Cell Reports 33, 108533, December 29, 2020Freshly isolated lineage-negative (Lin) BM cells were trans-
duced with the titered shRNAs pooled library (MOI < < 1),
selected with puromycin, and subsequently injected into lethally
irradiated mice (Figure 1A). In this limited time window, Lin cells
weremaintained in vitro in the presence of HSC cytokines in con-
ditions known to preserve and enrich for stem cells/early progen-
itors (Ye et al., 2008). Indeed, early progenitors were maintained
during transduction, as gauged by the enrichment of the Linc-
Kit+Sca1+ (LSK) cells in fluorescence-activated cell sorting
(FACS) analysis (Figure S1A). Notably, the transduced cell cul-
ture also retained phenotypic HSCs, which was assessed by
the HSC SLAM (signaling lymphocyte activation molecule) sur-
face marker CD150+ that is expressed on cells endowed with
an immature phenotype and reconstitution potential (Christen-
sen and Weissman, 2001; Kiel et al., 2005; Yeung and So,
2009) (Figure S1A). Transduced Lin cells were mixed 1:1 with
total BM cells from CD45.1 mice (Figure 1A). To ensure optimal
representation of the shRNA library, we injected a minimum of
1 3 106 Lin transduced cells per mouse, aiming for least at a
predicted 2,000-fold library representation per animal, which is
estimated to be sufficient to control for grafting efficiency and
stochastic drifts (Gargiulo et al., 2014; Serresi et al., 2018).
We allowed cells to engraft recipient animals and harvested
blood, BM, and spleen from recipient mice at 4 weeks post-
transplantation (wpt). We chose a 4-week time point as readout
based on experimentally determined parameters. First, we veri-
fied that 4 weeks is a sufficiently long period of time to allow
assessment of potential phenotypic defects of the murine pro-
genitors during the acute proliferative phase. This included
both expansion and depletion, thereby enabling us to identify
genes regulating either quiescence or proliferation. Second,
4 weeks is a time frame consistent with polyclonal engraftment
and insufficient to allow manifestation of compensatory mecha-
nisms and HSC clonality issues. In fact, in long-term engraftment
experiments (4–6 months), only a small number of HSCs
contribute tomost cellular output (Naik et al., 2013). In our exper-
iments, we observed measurable grafting in recipients and the
generation of donor-derived B cells in the spleen of transplanted
recipients (Figures S1B and S1C). This supports the 4-week time
point as being sufficient to enable the screen while limiting HSC
clonal expansion.
FACS analysis of BM, circulating blood cells, and splenocytes
showed successful engraftment of the transduced Lin cells,
with an average of 50% contribution in the BM (Figures 1C,
S1B, and S1C). To assess the relative representation of each
shRNA in vivo, we then performed parallel next-generation
sequencing of PCR-amplified shRNA sequences from genomic
DNA in the following conditions: (1) in vivo hematopoietic precur-
sors and differentiated cells, isolated at 4 wpt from the BM (Lin
cells) or the spleen (CD43, CD45.2+, CD19+, CD220+ B cells),
respectively, of recipients; and (2) control transduced Lin cells
immediately before injection (input, or time 0 [T0]), as well as the
plasmid library. Sequencing of individual samples revealed that
individual shRNA abundance in transduced Lin (T0) correlated
well with the hairpin reads in the plasmid library, supporting effi-
cient transduction in vitro (R2 = 0.69; Figure S2A). Importantly,
more than 97% of the hairpins could be identified in the trans-




Figure 1. Pooled In Vivo RNAi Screen Identifies Candidate DUBs Effectors of Hematopoietic Stem and Progenitor Cell (HSPC) Activity
(A) Overview of the DUB RNAi screens in vivo.
(B) Primary and secondary screens parameters.
(C) Representative FACS profiles of Lin fraction purified from recipients at 4 wpt and analyzed for chimerism.
(D) Consolidated fraction of shRNAs retrieved in vivo in Lin cells at 4 wpt and controls.
(E) Volcano plot depicting the log2 fold change (FC) in the BM of recipients of all hairpins used in the primary screen, normalized across five replicates.
(F) Venn diagram depicting significantly differentially represented genes overlapping between the primary and secondary screens.
(G) Volcano plot depicting the log2 FC in the BM of recipients of all hairpins used in the secondary screen (DUB2 sub-library), normalized across seven replicates.
Significantly (adjusted p % 0.02) dropout (log2 FC % 1, blue), and enriched (log2FC R 1, red) shRNAs are shown in (E)–(G).
See also Figures S1 and S2.
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OPEN ACCESSpurified Lin cells from each recipient mouse (4 wpt). We
concluded that a significant proportion of the initial library
complexity is maintained in vitro and in vivo (Figures S2A and 1D).
Principal-component analysis (PCA) showed that the five in vivo
BM samples were more similar to each other and were distinct
from the input cells before injection, and limited variance between
the individual samples was found (Figures S2B and S2C). More-
over, a positive correlation was found between the relative repre-
sentation of shRNAs retrieved from the BM to the ones retrieved
from the spleen (R2 = 0.668) (Figure S2D; Table S3).
Next, we performed a differential enrichment analyses on the
in vivo and control samples. Among the top hits, we found genesrelevant to HSC biology to be either enriched (involved in cell cy-
cle restriction) or depleted (supporting self-renewal), including
our positive controls. Consistent with the requirement for Bmi1
in adult HSC self-renewal (Park et al., 2003), two out of the four
shRNAs targeting Bmi1 showed significant dropout (>20-fold)
in Lin cells in vivo (Figure 1E; Table S3). DNA repair genes
BRCA1 and BRCA2/FANCD1 were also highly depleted with at
least one shRNA per gene, in line with their role in HSC survival
(Navarro et al., 2006; Vasanthakumar et al., 2016). Consistent
with a role in cell-cycle restriction (Wang et al., 2012), two
shRNAs for the cell-cycle inhibitor Cdkn1a were enriched (Fig-
ure 1E). Notably, DUBs with established importance in HSCCell Reports 33, 108533, December 29, 2020 3
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OPEN ACCESSmaintenance, including USP1 (Parmar et al., 2010), USP3 (Lan-
cini et al., 2014), and USP16 (Adorno et al., 2013; Gu et al.,
2016), also scored top hits from the primary screen and were tar-
geted by two independent shRNAs (Figures 1F and S2H; Table
S3).
To validate our primary screen, we divided the primary library
in two mostly nonoverlapping shRNA sub-pools (DUB1 and
DUB2 sub-library) and performed secondary screens under
similar transplantation conditions (Figures 1B, 1F, and S1C). In
line with the primary screen, high hairpins representation
in vitro and in vivo (>95%), low variance between individual
mice, and the performance of positive control shRNAs support
the overall good quality and reproducibility of the secondary
screens (Figures 1F, 1G, and S2E–S2G; Table S3). Although
many shRNAs showed similar changes in representation in the
primary and in the secondary screens, a measurable variation
was present, likely due to inconsistencies in transduction effi-
ciency or to the stochastic gain or loss of shRNAs following in vivo
growth (Table S3). To overcome this, we adopted stringent se-
lection parameters. We considered as candidates those genes
for which at least two shRNAs were depleted/enriched by 10-
fold median in the BM relative to their representation in the T0
control (i.e., the injected cell population; adjusted p value %
0.02) in each screen and that were called as hits in at least two
independent experiments. When multiple hairpins showed
opposite effect, the corresponding gene was excluded. By these
criteria, our positive controls and 14 out of 81 DUB genes tested
were validated in the secondary screens and defined as positive
hits (Figures 1F and S2H).
To prioritize hits for follow-up, we focused on DUBs with re-
ported high expression in LSK and in HSC (Cabezas-Wallscheid
et al., 2014; Lancini et al., 2016). We focused on USP15, for
which three independent shRNAs were depleted for >15-fold
median in the BM after 4 weeks, and the top-scoring shRNAs
showed a 60-fold dropout (Figures 1E and 1G; Table S3).
USP15 (Baker et al., 1999) is expressed in the early progenitor
compartment (LSK) and HSCs, as well as in blood and splenic
B cells, and, among the depleted DUBs, it ranks as third in
expression in LSK (Cabezas-Wallscheid et al., 2014; Lancini
et al., 2016).
Together with our screen results, these data suggest a poten-
tial role for USP15 in hematopoiesis, though no functional studyFigure 2. USP15 Depletion Impairs HSPC Proliferation In Vitro and Rec
(A) In vitro and in vivo validation assays for USP15-targeting shRNAs.
(B) Knockdown efficiency of shRNAs targeting USP15 in Lin cells as measured
(C) Flow cytometry analysis of Lin cells at 1 week post-infection. The frequency o
LSKs in the live culture, was calculated and normalized relative to shScramble c
(D) Freshly purified Lin cells were plated 7 days post infection and monitored fo
(E–K). Freshly isolatedWT Lin cells transducedwith the indicated shRNAswere a
per shRNA, except for shUSP15#16 (n = 4).
(E and F) CD45.2 chimerism in peripheral blood (E) and contribution of transduced
of recipients. PBC, peripheral blood cells.
(G) CD45.2 chimerism in B cell and T cell lineages in recipients’ spleen at 18 wp
(H) Representative FACS profiles of the LSK compartment in recipients at 18 wp
(I) CD45.2 chimerism level in LSKs in primary recipients (left). Right: numbers of
(J) Cell numbers of donor-derived HSCs (LSK/CD150+/CD48) in 106 viable BM
(K) Fraction of donor-derived LKSs, CMPs, GMPs, and MEPs in primary recipie
*p % 0.05; **p % 0.01; ***p % 0.001. p value was assessed by Student’s t test oin vivo has yet been reported. We therefore decided to further
investigate the role of USP15 in HSC biology.USP15 Depletion Impairs HSPC Proliferation In Vitro
We first checked USP15 expression levels in normal hemato-
poiesis by surveying published gene expression datasets. In
the mouse BM, Usp15 expression is consistently high at the
single-cell level, and expression is homogeneous in the entire
hematopoietic tree, being expressed at similar level in single
mouse long-term HSCs (LT-HSCs) and early lineage-
committed progenitors (Figures S2I and S2J) (Nestorowa
et al., 2016; Olsson et al., 2016). Importantly, Usp15 expres-
sion pattern in the mouse is similarly conserved in humans,
as inferred by USP15 expression in CD34+ human HSCs
and early lineage-committed progenitors at the single-cell
level (Figure S2K) (Pellin et al., 2019).
We addressed the impact of individual USP15-targeting
shRNAs on hematopoietic progenitors in vitro and in vivo (Fig-
ure 2A). We first assessed the ability of the single shRNAs to
reduce Usp15 expression upon low MOI (<1). To cope with the
paucity of Lin cells, we chose qRT-PCR as a readout. All three
shRNAs identified in the secondary DUB screen (DUB2 sub-li-
brary; Figure 1G; Table S3) downregulated USP15 mRNA
expression in freshly isolated, lentiviral-infected Lin cells (Fig-
ure 2B) and USP15 protein levels in primary murine lung cancer
cells (Figure S3A). For functional validation, we prioritized the
two top-scoring lentiviral shRNA vectors in the screen, and
Lin cells were transduced with either a control (shScramble)
or USP15-targeting #sh16 and #sh17 shRNAs. To determine
the effect of USP15 depletion on the LSK compartment, the
transduced cells were propagated in a serum-free medium sup-
plemented with pro-self-renewal growth factors and analyzed by
flow cytometry for the presence of LSK surface receptors at
1 week post-infection. Within the Lin, c-Kit+ population, the
fraction of LSKs remained comparable between USP15-
depleted and control shRNA cells (Figure 2C, left panel). Never-
theless, the expansion of both Lin, c-Kit+ and LSK cells was
affected by USP15 depletion compared to control shRNA (Fig-
ure 2C, middle and right panels, and Figure S3B). Consistently,
USP15 knockdown progenitors exhibited limited proliferation
(Figure 2D).onstitution Potential In Vivo
by qRT-PCR. Mean values of three technical replicates ± SD are shown.
f LSKs in the Lin, c-Kit+ population, as well as the frequency of Lin, c-Kit+, and
ontrol. n = 3 independent experiments. Mean values ± SEM are shown.
r growth. n = 4 wells per data point. Mean values ± SEM are shown.
ssayed in competitive BM transplantation.Mean values ±SEMare shown. n = 3
cells tomyeloid (Gr1+), B cell (CD19+), and T cell (CD3+) lineages in the blood (F)
t.
t.
donor-derived LSKs in 106 viable BM cells at 18 wpt.
cells at 18 wpt.
nts at 18 wpt.
r multiple t test (D) in Prism 7. See also Figure S3.




Figure 3. Reduced HSC Compartment in Usp15 Knockout (KO) Mice
Flow cytometry analysis of the hematopoietic primitive populations in 8- to 12-week-old Usp15+/+ and Usp15/ mice.
(A) Representative FACS profiles of the Lin, c-Kit+, LSK, and HSC populations. Frequency of HSCs in the live cell population is presented.
(B) Lin, c-Kit+ cell numbers per million live BM cells.
(C) LSK cell numbers per million live BM cells.
(D) HSC (LSK, CD150+, CD48/) cell numbers per million live BM cells.
(E) Frequency of Lin, c-Kit+, LSK and HSC in BM of Usp15/ mice was calculated and normalized to Usp15+/+ animals.
Results are from three (Lin, c-Kit+, and LSK; Usp15+/+ n = 9; Usp15/, n = 5) or four (HSC; Usp15+/+, n = 13; Usp15/, n = 7) independent experiments. *p%
0.05, ****p % 0.001; n.s., not significant. Error bars represent ± SEM. See also Figure S4.
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OPEN ACCESSUSP15 Depletion Impairs Stem and Progenitor Cell
Reconstitution Potential In Vivo
We then transducedmurine Lin progenitors with USP15-target-
ing or control shRNAs and competitively co-transplanted these
CD45.2 USP15-depleted or control progenitors together with
freshly isolated CD45.1 BM cells (1:1 ratio) into lethally irradiated
recipients. Within a period of 18 weeks, USP15 knockdown Lin
cells failed to contribute to a chimerism level beyond the 20% of
total peripheral blood cells, whereas the chimerism level of con-
trol mice progressively increased, reaching the expected 50%
contribution (Figure 2E). This underscores a competitive disad-
vantage of USP15-depleted cells compared to control cells. At
18 wpt, we found that all lineages within CD45.2 USP15-
depleted peripheral blood cells, including myeloid/granulocytes
(CD11b+, GR1+ cells), B cells, and T cells, were equally affected
as compared to their control counterparts (Figures 2F and S3C).
As observed in the blood, USP15 loss affected multilineage
reconstitution (B cells and T cells) of recipient animals’ spleen
at 18 wpt, with an average 52% of control B cells compared to
25% and 10.8% of USP15-#sh16 and USP15-#sh17 cells,
respectively (Figures 2G and S3D). As expected, the total cell
numbers in the spleen and BM of euthanized recipient mice
were comparable (Figure S3E).
The above results suggest a defect in the multilineage recon-
stitution potential of USP15-depleted progenitors. Given that6 Cell Reports 33, 108533, December 29, 2020BM-resident HSCs are mainly responsible for giving rise to and
maintaining all blood cell lineages (Kiel et al., 2005; Naik et al.,
2013; Wilson et al., 2008), we quantified the numbers of
CD45.2+ cells in the BM of recipients transplanted with either
USP15-depleted or control progenitors at 18 wpt (Figures 2H–
2K, S3F, and S3G). We then assessed stem cell reconstitution.
In line with the overall lower relative contribution to the blood
(Figure 2F), we measured a defect in USP15-depleted BM pre-
cursors. USP15-depleted LSKs were reduced in frequency and
numbers (2.38- and 8-fold reduction, respectively) compared
to control (shScramble) LSKs, which reached 50% contribution
to the LSK compartment in recipient mice (Figures 2H, 2I, and
S3F). To specifically focus on HSCs, we then employed the
HSC surface receptors SLAM CD48 and CD150 markers (Cabe-
zas-Wallscheid et al., 2014; Kiel et al., 2005; Oguro et al., 2013).
We found a significant decline (3.25-fold) of CD42.2 HSCs (as
defined by LSK/CD48/CD150+) in the BM of animals reconsti-
tuted with USP15-depleted cells compared to controls (Figures
2J and S3F).
USP15 depletion resulted in a consistent decrease in donor-
derived cells also in the more differentiated, proliferative LKS
(LinSca1c-Kit+) progenitors. A similar reduction of USP15-
depleted cells compared to controls was measured in the
myeloid subsets of common myeloid progenitors (CMPs) and
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OPEN ACCESSmegakaryocyte-erythrocyte progenitors (MEPs) (Figures 2K and
S3G) (Yeung and So, 2009), confirming an important role for
USP15 in preserving all the main hematopoietic differentiation
pathways.USP15 Knockout (KO) Compromises Normal HSC
Function In Vivo
To assess the role of USP15 in physiological hematopoiesis, we
generated mice deficient for USP15 (Pritchard et al., 2017) (Fig-
ure S4A). Deletion of the Usp15 locus was confirmed by PCR
genotyping and western blot (Figures S4B and S4C). Homozy-
gous Usp15/ mice were viable, indicating that USP15 is
dispensable for embryonic development. However, Usp15/
animals were born at sub-Mendelian ratio and showed reduced
survival and lower body weight when compared to Usp15+/+
mice, confirming a critical role for USP15 in vivo (Figures S4D–
S4F). Some of the Usp15 KO animals showed evidence of in-
flammatory lesions (Figures S4G and S4H; Table S7).
We next screened young adult Usp15+/+ and Usp15/ litter-
mates (8–14 weeks) for BM cellularity. No marked differences
were found, suggesting that USP15-deficient BM can develop
to a large extent normally (Figure S4I). In line with this, pheno-
typic analysis revealed a normal frequency in the Lin, c-Kit+
population in Usp15/ and control mice (Figures 3A, 3B, 3E,
and S4M), with a modest (but not significant) reduction in the
Usp15/ more undifferentiated stem and progenitors, the
LSKs (Figures 3A, 3C, 3E, and S4M). Notably, within LSKs, the
frequency and numbers of immature precursors endowed with
reconstitution potential (LSK, CD135, CD150+) (Christensen
andWeissman, 2001; Kiel et al., 2005; Yeung and So, 2009) (Fig-
ures S4J–S4L) and, more specifically, phenotypic HSCs (LSK,
CD48, CD150+) (Cabezas-Wallscheid et al., 2014; Kiel et al.,
2005; Oguro et al., 2013) were significantly lower in KO mice,
reaching only 60% of their aged-matched wild-type (WT) con-
trols (Figures 3A, 3D, 3E, and S4M). The more committed
(myeloid) progenitor pools did not show any measurable pheno-
type (Figure S4N). Consistently, Usp15/ BM cells performed
similar toWT BMwhen assayed in vitro in myeloid colony-forma-
tion assays (colony-forming units in culture [CFU-Cs])
(Figure S4O).
To establish whether the HSCs remaining in Usp15 KO mice
are functionally equivalent to those in WT littermates, we per-
formed competitive BM transplantations. Upon transplantation
of BM cells containing a 1:1 mixture of test and competitor cells,
chimerism of CD45.2 Usp15/ peripheral blood cells in recipi-
ents significantly decreased over time compared to mice trans-
planted with Usp15+/+ BM (Figure 4A). Usp15+/+ chimerism re-
mained constant throughout the 18 weeks of analysis andFigure 4. Genetic KO of Usp15 Impairs HSC Function
(A–E) Competitive transplantation of BM cells freshly isolated from Usp15+/+ or U
(A and B) Chimerism in peripheral blood (A) and contribution of BM cells to myeloi
(C) Representative FACS profiles (left) and numbers of donor-derived LSKs per m
(D) Representative FACS profiles (left) and numbers of donor-derived HSCs (LSK
(E) Numbers of donor-derived myeloid committed progenitor populations (LKSs
(F) FACS-sorted LSKs were plated after 8 days (second plating) in culture and mo
and 8 of the second plating are shown. Bar, 20 mm.
*p % 0.05; **p % 0.01; ***p % 0.001. Error bars represent mean ± SEM (A–E); da
8 Cell Reports 33, 108533, December 29, 2020reached the expected plateau. Importantly, USP15 deletion crit-
ically affected myeloid/granulocytes (CD11b+/Gr1+) as well as
lymphoid blood cells (CD19+ B cells and CD3+ T cells) (Figures
4B and S3C). This phenotype recapitulates the USP15 knock-
down defects observed upon transplantation of shRNA-trans-
duced Lin cells (Figures 2E and 2F). In recipient BM at 18
wpt, we found significantly lower numbers of Usp15/ LSKs
as well as HSCs (LSK, CD150+, CD48) compared to WT con-
trols, suggesting that USP15-deficient HSCs have reduced
self-renewal capacity in recipients compared to WT HSCs (Fig-
ures 4C, 4D, and S5A). Consequently, the more committed
Usp15/ LKS and CMP pools were diminished (Figures 4E
and S5B).
We next examined the consequences of USP15 deletion on
HSPC cellular homeostasis. By DAPI/immuno-phenotyping
combined analysis of freshly isolated BM cells, we measured
that Usp15/ mice have similar numbers of quiescent HSPCs
compared to WT mice. The majority of HSCs were in the G0/
G1 phase of the cell cycle. Under these physiological conditions,
no subsets of HSPCs or HSCs differed significantly in terms of
percentage of cells in S/G2 phase (Figure S5C). Of note, freshly
isolated Usp15/ stem and progenitor cells did not show
apparent apoptosis (Figure S5D). Cleaved-caspase-3-positive
cells were not readily detected on BM tissue sections of
Usp15/ mice (Figure S5E). RNA sequencing (RNA-seq) of
WT and Usp15/ LSKs confirmed the loss of Usp15 and the
maintenance of an overall stable identity of the cellular compart-
ment (Figure S5F).
Having established a functional defect inUsp15/ LSKs upon
transplantation, we next assayed their intrinsic proliferative ca-
pacity in conditions of cytokine-induced replication. In in vitro
liquid cultures, FACS-sorted Usp15/ LSKs displayed a signif-
icantly reduced proliferative capacity compared to WT, which
was exacerbated upon ex vivo culturing (Figure 4F).USP15 Is Highly Expressed in Human Leukemia
LSCs share functional properties with normal HSCs. Acute
myeloid leukemia (AML) and chronic myeloid leukemia (CML)
arise in the early hematopoietic compartment and have LSCs en-
dowed with self-renewal and ability to propagate the disease
(Kreso and Dick, 2014; Warr et al., 2011).
Consistent with this, USP15 featured the highest of expression
in human hematopoietic tissues and related cancers, including
leukemia and lymphomas (The Cancer Genome Atlas [TCGA])
(Figures 5A and 5B). In an AML-specific dataset, USP15 expres-
sion was significantly higher in patients with AML carrying
various genetic abnormalities compared to the normal human
CD34+-enriched BM hematopoietic precursors (Figure 5C)sp15/ mice.
d (Gr1+), B cell (CD19+) and T cell (CD3+) lineages in the blood (B) of recipients.
illion viable BM cells in recipients at 18 wpt.
/CD150+/CD48) per million viable BM cells in recipients at 18 wpt.
, CMPs, GMPs, and MEPs) in recipients at 18 wpt.
nitored for growth. n = 4 wells per data point. Representative images at days 3





Figure 5. USP15 Is Highly Expressed in Primary Blood-Derived Cancer
(A) Cohort TCGA pan-cancer (PANCAN) (total number of samples, 11,060) shows upregulation of USP15 in AML.
(B) Cohort TCGA PANCAN (11,060) shows upregulation of USP15 in blood-derived tumors.
(C) Log2-transformed expression of USP15 from microarray-based gene expression profiling of human BM cells (Hemaexplorer). TPM, transcripts per kilobase
million.
(D) Kaplan-Meier curve correlating survival of 10,951 PANCAN patients with USP15 gene expression. TCGA PANCAN samples used in this analysis are shown in
Table S8.
(legend continued on next page)






OPEN ACCESS(Bagger et al., 2013) (Hemaexplorer; http://servers.binf.ku.dk/
bloodspot/). Of note, high expression of USP15 is statistically
associated with tissue-independent poor survival within the
pan-cancer (PANCAN) patient cohort, a feature generally associ-
ated with oncogenes (Figure 5D; Table S8).
To test whether these data are reflected in human cancer
models, we next analyzed USP15 expression in the large panel
of comprehensively characterized Cancer Cell Line Encyclo-
pedia (CCLE). In line with the previous analyses, the highest
expression was found in leukemia cell lines, including multiple
AMLandCMLcell lines, compared to all other tissues (Figure 5E).
To experimentally validate these analyses, we profiled USP15
expression in a panel of 23 leukemia cell lines, including all matu-
ration stages and chemotherapy-resistant CML lines. With the
sole exception of the KG1/KG1a cell line, USP15 mRNA was
high in all the tested lines and independent of the leukemia stage.
Interestingly, K562 and KBM7 blast crisis lines have very high
USP15 expression (Figure 5F).
To test whetherUSP15 gene expression correlates with its ge-
netic dependency, we ranked the dependency scores calculated
by DEMETER2 (D2) for USP15 RNAi in CCLE lines (McFarland
et al., 2018). According to DepMap (https://depmap.org/
portal), USP15 expression and dependency varied across cell
lines but were not linearly correlated, and leukemia cell lines
were not specifically sensitive compared to other cancers (Fig-
ure S6A). Next, we investigated whether cancer-related biolog-
ical pathway activation would be informative as a biomarker for
USP15 dependency. To this end, we compiled a list of cell lines
in which sensitivity to USP15 depletion was experimentally
tested and could be classified as relatively high (<0.2) or low
(>0.2) by D2 score. Among the leukemia cell lines, MV-4-11
and Kasumi-1 featured highly sensitive and SEM and K562
featured as less sensitive cell lines (Figure S6A). Using PROG-
ENy (Schubert et al., 2018), differential pathway activation be-
tween cell lines with varying degrees of sensitivity indicate that
several RTK (receptor tyrosine kinase), JAK/STAT, and phospha-
tidylinositol 3-kinase (PI3K) signaling pathways tend to anti-
correlate with sensitivity to USP15 depletion, whereas VEGFA,
HIF1A, and transforming growth factor beta (TGF-b) signaling
were found more active in highly sensitive cell lines (Figure S6B).
Across the whole spectrum of CCLE cell lines, however, there
was no evident biomarker for response, except a trend for acti-
vation of the Trail pathway (Figure S6C), suggesting that USP15
depletion may operate in context-dependent manner. To exper-
imentally address the potential impact of the regulation of these
pathways in response to USP15 depletion, we next performed
RNAi of USP15 on highly expressing KBM7 and K562 CML cell
lines. The K562 cell line is considered to have low sensitivity
within the DepMap dataset, and therefore, response to USP15
RNAi may be uncoupled from survival. Ingenuity pathway anal-
ysis identified 657 and 330 differentially regulated genes in
KBM7 and K562, respectively. In line with PROGENy analysis,
RNAi of USP15 led to activation of inflammation-related path-(E) Expression of USP15 from transcriptional profiling of human cancer cell lines
(F) USP15 normalized expression levels in a panel of leukemia cell lines as assess
FAB (French-American-British) stage for leukemia subtype classification.
See also Figure S6.
10 Cell Reports 33, 108533, December 29, 2020ways, which involve JAK/STAT and PI3K signal transduction
(Figures S6D–S6G). In K562, we also measured significant
down-modulation of TGF-b signaling (Figures S6H and S6I).
USP15 Loss Enhances Genotoxic Stress in Leukemia
Cell Lines and Mice
Given the context-dependent responses to USP15 depletion in
CML cells and that reversal of ubiquitination often contributes
to fine-tuning of the DDR (Nishi et al., 2014), we next focused
on exploring a potential role for USP15 in genome maintenance.
USP15 depletion by USP15-targeting small interfering RNAs
(siRNAs) mildly but reproducibly reduced the viability of both
‘‘less sensitive’’ K562 and KBM7 and ‘‘more sensitive’’ MV411
and Kasumi-1 cell lines (Figures 6A, 6B, and S6A; see below).
Despite the predicted low sensitivity to USP15 depletion,
USP15 loss was accompanied by a significant increase in the
number of spontaneous nuclear foci of the DDR factor 53BP1
as well as an increase in the basal levels of g-H2AX, a DNA dam-
age marker, and the frequency of micronuclei in both K562 and
KBM7 cells (Figures 6C–6F), all indicative of enhanced genotoxic
stress. Thismirrors the increase inmicronucleation, as well as bi-
and multinucleation and apoptotic/necrotic cells observed in
FACS-sorted LSKs from the BM of Usp15/ mice upon
culturing (Figure 6G) and their increase in spontaneous g-H2AX
nuclear foci (Figure 6H), thereby indicating that USP15 loss af-
fects genome integrity in all of these settings. Spontaneous gen-
otoxic stress was also observed in USP15 depleted osteosar-
coma cells (Figures S7A–S7H), thereby extending the validity
of USP15 expression as genome integrity safeguard mechanism
to multiple tissue neoplasia.
These data supported the hypothesis that USP15 depletion
would render normal HSPCs more sensitive to genotoxic stress
in vivo. To test this, we injected mice with the chemotherapeutic
agent cisplatin (Pilzecker et al., 2017) intravenously (i.v.), or with
PBS, and analyzed the BM after 2 days. Upon cisplatin treat-
ment, USP15 KO BM cells produced significantly fewer CFUs
compared to WT (Figure S7I), suggesting higher sensitivity of
their HSPC compartment. Deeper BM analysis unmasked a
broader sensitivity of the primitive progenitor compartment in
Usp15/ mice, including HSCs and LSKs and the more prolifer-
ative LKS, myeloid (GMP), and lymphoid (CLP) progenitor pop-
ulations, to genotoxic stress (Figures S7J and S7K).
Finally, we sought to translate these findings into a potential
combination setting in leukemia. In leukemia cells originated by
blast crisis such as KBM7 cells, we combined depletion of
USP15 by doxycycline (dox)-inducible RNAi and DNA breaks in-
duction by ionizing radiation (IR). USP15 depletion by a dox-
inducible shRNA sensitized KBM7 cells to IR (Figure 6I). In keep-
ingwith a role of USP15 in DDR (Peng et al., 2019), Rad51 protein
levels were diminished by USP15 knockdown inMV4-11 and Ka-
sumi-1 leukemia cells (Figure S7L). A broader chemo-profiling in
CCLE cancer cell lines indicated that leukemia cell lines are
generally more sensitive than others to the DNA damage(CCLE, Broad Institute).









Figure 6. USP15 Loss Enhances Genotoxic Stress in Human CML Leukemic Cells and Mouse Normal Hematopoietic Progenitors
(A–F) K562 and KBM7 CML cell lines transfected with USP15 (siUSP15) or non-targeting (siCtrl) siRNAs and assayed at 72 h after transfection.
(A) Immunoblotting on whole-cell extracts.
(B) Cell viability. Mean ± SD from three independent experiments are shown.
(C) Representative images and quantification by ImageJ of the number of spontaneous 53BP1 foci/cell. Mean values ± SEM are shown. n = 2. A minimum of 250
cells per sample was counted over two independent experiments.
(D) Immunoblotting of USP15-depleted cell lines.
(E and F) Quantification and representative images of micronuclei (MN; arrows) in KBM7 (E) and K562 (F). Results are mean ± SD from three independent ex-
periments. A minimum of 150 (KBM7) or 450 (K562) cells was scored.
(G) Percentage of MN in FACS sorted, murine LSK after 11 d in culture. A minimum of 60 cells/genotype was scored in two independent experiments (each
experiment: Usp15+/+, n = 3; Usp15/, n = 2). Mean ± SD is shown.
(H) Immunofluorescence staining for gH2AX on LSK after 5d in culture. Percentage of cells containing >5 spontaneous gH2AX nuclear foci and representative
images are shown. A minimum of 60 cells/genotype/sample was scored per experiment in two independent experiments (each experiment: Usp15+/+, n = 3;
Usp15/, n = 2). Mean ± SEM is shown.
(legend continued on next page)






OPEN ACCESSinducers topotecan and mitomycin-C (MMC), two chemothera-
peutic clastogenic agents (Figure 6J). Notably USP15-depletion
cooperated with MMC to reduce cell viability in MV4-11
(Figure 6K).USP15 Regulates FUS Stability in Leukemia Cells
To gain mechanistic insight into how USP15 contributes to pre-
serve genome integrity, we next determined USP15 interactors
in MV4-11 and Kasumi-1 cells, which are sensitive to acute
USP15 depletion (Figure S6A). To isolate USP15 direct interac-
tors, we immunoprecipitated endogenous USP15 in both naive
and DNA stress conditions (MMC; Figures 7A and 7B). By
mass spectrometry, we identified 355 candidates that co-immu-
noprecipitated with USP15 in all the conditions. Stringent
filtering of high-confidence interactors (n = 4/condition, adjusted
p < 0.05 against immunoglobulin G [IgG]) returned 38 USP15 in-
teractors shared by MV4-11 and Kasumi-1 cell lines, including
known interactors (e.g., USP4 and USP11; Figure 7C). Impor-
tantly, 33 (87%) were not previously reported as USP15 inter-
actors in BioGRID (Figure 7C). To focus on DDR-related pro-
cesses, we used pathway analysis of the 38 candidates by
Reactome. Consistent with a potential role for USP15 in DDR,
we found that FUS, TAF15, USP11, USP4, and CHMP4B pro-
teins are associated with DNA repair, and MCM5 is associated
with DNA replication processes (Figure 7D). We focused on
FUS, a bona fide USP15 interactor based on identity score, pep-
tide number, and interaction intensity in both MV4-11 and Ka-
sumi-1, including under DNA stress conditions (Figure 7D).
FUS is an RNA/DNA-binding protein that is reported to pro-
mote HSC self-renewal (Sugawara et al., 2010) and is highly ex-
pressed in leukemia cell lines (https://depmap.org/portal). FUS
contributes to DNA repair by promoting DNA homologous pair-
ing (Bertrand et al., 1999) and D-loop formation (Baechtold
et al., 1999), as well as by facilitating DDR site loading with
HDAC1 (Wang et al., 2013) and compartmentalization of
damagedDNA (Singatulina et al., 2019).We validated the endog-
enous interaction between USP15 and FUS by direct and
reverse co-immunoprecipitation in both MV4-11 and Kasumi-1
(Figure 7E-G). Given that USP15 can potentially regulate the sta-
bility of its interactors and FUS is exported from the nucleus to
the cytoplasm after DNA repair (Singatulina et al., 2019), we
investigated whether USP15 was altering FUS stability or loca-
tion and in which cellular compartment. To this end, we gener-
ated MV4-11 USP15 KO cells by CRISPR-Cas9 KO, and we
analyzed the nuclear and the cytoplasmic fractions by immuno-
blot. USP15 depletion reduced FUS levels in the cytoplasm, but
not in the nucleus (Figure 7H). In line with previous reports,(I) KBM7 cells transduced with a doxycycline (dox)-inducible shUSP15 were grow
measured 3 days after IR. Values represent mean ± SD of two independent expe
(J) Scatterplot of area under the dose-response curve (AUC) scores indicating se
dots indicate leukemia cell lines. Data are generated by Cancer Target Discover
Response Portal (CTRP).
(K) MV4-11 cells harboring USP15 shRNA were kept in medium with or without do
were performed at 72 h of MMC treatment. Results are the mean ± SEM of three
sample).
*p % 0.05; **p % 0.01; ****p % 0.0001. In (I), ****p < 0.0001 (assessed by two-
nucleoplasmatic bud (NBUD). See also Figure S7.
12 Cell Reports 33, 108533, December 29, 2020USP15 was mainly localized in the cytoplasm, whereas FUS
wasmore nuclear (Urbé et al., 2012). Of note, FUS cytoplasmatic
depletion in USP15 KO cells occurred without altering FUS nu-
clear levels (Figure 7H). Importantly, proteasome inhibition by
low-dose bortezomib restored FUS levels in the cytoplasm of
USP15 KO cells, supporting a role for USP15 in protecting FUS
from proteasomal degradation (Figure 7I).DISCUSSION
We report on the comprehensive assessment of the role for
DUBs in early hematopoiesis through pooled in vivo shRNA
screens in the mouse. Using this unbiased approach, we uncov-
ered several genes within the family of DUBs whose loss in-
creases or decreases mouse HSPC fitness in vivo. The top hit
in our screens was USP15, which we herewith report as a DUB
required for early hematopoietic progenitor proliferation and for
HSC homeostasis in vivo. USP15 had a positive role in preser-
ving normal stem and leukemic cell genome integrity and medi-
ated the stability of a HSC self-renewal and DNA repair factor,
FUS (fused in sarcoma).
Pooled in vivo screens in early progenitors pose specific tech-
nical challenges. The success of our shRNA screening approach
is underscored by the maintenance of our shRNA library repre-
sentation in vitro and in vivo and the ability to identify established
regulators of HSC biology, including known DUBs. Together with
the extensive genetic validation, these examples raise confi-
dence in the identification of USP15 as critical regulator of
HSCs in vivo.
Loss of USP15 in adult murine hematopoietic progenitors by
RNAi or germline deletion impaired their growth in vitro and repo-
pulation ability in vivo. Our data support the defective initial and
long-term hematopoietic engraftment to contribute to USP15-
deficient HSC loss during transplantation. HSC/HSPC cells un-
der physiological conditions in vivo did not display measurable
cell-cycle abnormalities, which is consistent with either a role
for USP15 during active replication or with technical limitations
in the sensitivity of the assay. Future studies to address the pro-
liferative status/cell-cycle progression will require single-cell as-
says of purified primary USP15 deficient HSC ex vivo or intravital
imaging.
Under homeostatic conditions, genetic deletion of USP15
specifically affected the HSC reservoir in adult mice, while the
more differentiated progenitors were largely maintained. Of
note, the functional defect we observed in BM transplantation
upon USP15 knockdown is reasonably comparable to that
observed in Usp15 KO cells under competitive repopulationn with or without dox for 5 days and seeded for IR treatment. Cell viability was
riments (each with n = 5 replicates/sample) (two-way ANOVA, ****p < 0.0001).
nsitivity of individual cell lines to either topotecan or mitomycin-C (MMC). Red
y and Development (CTD2) Network and taken from the Cancer Therapeutics
x for 5 days and plated with 30 nMMMC. Western blot and cell viability assays
(MMC) or two (+MMC) independent experiments (each with n = 3 replicates/
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OPEN ACCESSstress. We interpreted these data as the chronic lack of USP15 is
compensated by protective pathways/adaptation to ensure he-
matopoiesis at steady state, whereas the acute loss of USP15
along with the repopulation stress unleashed a stronger pheno-
type. The net outcome is that USP15 is still required, but the
extent of its requirement depends on the context (Chen et al.,
2020). These data are consistent with a role for USP15 in contrib-
uting to homeostasis through the maintenance of HSCs, which
are largely quiescent (Bakker and Passegué, 2013).
We report that spontaneous genotoxic stress and enhanced
sensitivity to clastogenic agents accompanied the decrease in
viability of USP15-deficient hematopoietic progenitors and leuke-
mia cells in vitro and mouse primitive hematopoietic progenitors
in vivo. These data link USP15 to the DDR and are consistent
with previous work in cancer cell lines (Fielding et al., 2018; Mu
et al., 2007; Nishi et al., 2014; Peng et al., 2019). Through de
novoproteomics, wedetermined theUSP15 interactome in leuke-
mia cells, directly linking USP15 to the regulation of known DDR
factors. In particular, USP15 stabilizes FUS, identified and vali-
dated as a functional USP15 interactor. While FUS’s contribution
to DNA repair is ultimately expected to take place in the nucleus
(Singatulina et al., 2019; Wang et al., 2013), we observed that
USP15 loss selectively affects cytoplasmic FUS. Physiological
FUS function depends on proper shuttling between the nucleus
and the cytoplasm (Naumann et al., 2018). Though several mech-
anisms may mediate FUS nucleo-cytoplasmatic shuttling (Deng
et al., 2014; Kaneb et al., 2012; Monahan et al., 2017; Singatulina
et al., 2019), its significance remains to be clarified (Rhoads et al.,
2018). The interaction between USP15 and FUS resulted in
lowering FUS cytoplasmic concentration, which may either affect
protein function or more simply reduce the overall amount of pro-
tein available for nuclear shuttling. Of note, immunoprecipitated
FUS was detected as two protein bands. This is in line with FUS
being regulated by several post-translational modifications
(Rhoads et al., 2018). Identifying these modificationsmay indicate
the activation by specific pathways and help to elucidate the mo-
lecular mechanism linking FUS activity to USP15 in DDR.
Whereas USP15 is known to interact with MDM2 (Zou et al.,
2014), in our experimental settings, we did not find evidence of
USP15 phenotypes being dependent on the p53 pathway, and
endogenous USP15 did not interact with MDM2 in our stringent
proteomic analysis. Together, the data suggest that USP15 may
support HSC self-renewal by contributing to swift DNA repair,
which is in line with HSC relying on fine-tuning of DDR (Bakker
and Passegué, 2013).Figure 7. USP15 Interacts with FUS and Promotes Its Stabilization in L
(A–D) USP15 interactome in MV4-11 and Kasumi-1 cell lines.
(A and B) Validation of endogenous USP15 immunoprecipitation previous to mas
30 nM MMC for 1 h.
(C) Venn diagram of USP15 interactors for each condition (adjusted p value% 0.05
USP15 interactors not previously reported in the BioGRID database. Bold text s
dicates DDR-related proteins as per Gene Ontology categories based on the Re
(D) Plot showing the parameters of identification for the indicated USP15 interacto
(E and F) Endogenous immunoprecipitation of USP15 in untreated or MMC-treat
(G) Reverse immunoprecipitation of endogenous FUS from MV4-11 cells co-imm
(H) Immunoblot of cytoplasmic and nuclear fractions in MV4-11 and MV4-11 US
(I) Immunoblot of USP15 WT and USP15 KOMV4-11 cells in the cytoplasmic and
blots for FUS and USP15 correspond to different exposures.
14 Cell Reports 33, 108533, December 29, 2020A functional role for USP15 in various cancers was previously
described (Eichhorn et al., 2012; Fielding et al., 2018; Padma-
nabhan et al., 2018; Peng et al., 2019). Here, we provide func-
tional ground for investigating the role for USP15 as gatekeeper
in leukemia. The functional interaction between USP15 and FUS
in blood cancer cells suggests that USP15 regulates DDR path-
ways in context-dependent manner. Hence, the role for USP15
in cell homeostasis is mechanistically broader than previously
anticipated. Understanding how USP15 loss precisely impacts
HSC and cancer cell maintenance and modulates their damage
responsemay help to identify combinatorial treatment that affect
leukemia self-renewal while sparing normal HSC from the side
effects of conventional chemotherapy.
USP15 is involved in multiple cellular processes, including p53
(Liu et al., 2017; Niederkorn et al., 2020; Zou et al., 2014) and nu-
clear factor kB (NF-kB) (Schweitzer et al., 2007) signaling. USP15
regulates inflammation in experimental models (Torre et al.,
2017; Zou et al., 2015) and promotes glioblastoma cell prolifera-
tion through stabilizing TGF-b signaling (Eichhorn et al., 2012).
Although the regulation of inflammatory signals and TGF-b are
relevant in both normal HSC and malignant development (Blank
and Karlsson, 2015), the limited changes in gene expression de-
tected in Usp15/ LSKs suggest that USP15’s function in
preserving genome integrity is dominant in this compartment.
However, our data raise the therapeutically interesting opportu-
nity to investigate whether the role for USP15 in preserving self-
renewal through genome integrity contributes to its functions in
glioblastoma.
The function of USP15 in development is still poorly charac-
terized. In addition to requirement for USP15 in HSC mainte-
nance, our KO mice had impaired Mendelian transmission
and lower lifespan. This phenotype is not obvious when
compared with reports in a USP15 gene-trap model (Zou
et al., 2014) but is in line with recent findings (Peng et al.,
2019). Our data warrant further investigation of the role of
USP15 at the organismal level.
In summary, we employed an unbiased approach to sensi-
tively and selectively screen for DUB function in hematopoietic
progenitors in vivo, through which we identified several DUB
candidates. Major investments in DUB drug discovery have
been made in the last 5–10 years, and more than 40 small mole-
cules against DUBs have already been developed (Harrigan
et al., 2018; Heideker and Wertz, 2015). Our data argue in favor
of developing specific USP15 inhibitors, which are only starting
to emerge (Teyra et al., 2019).eukemia Cells
s spectrometry analysis in MV4-11 cells (A) and Kasumi-1 cells (B) treated with
compared to IgG; n = 4) showing the 38 common interactors. Italic text shows
hows known USP15 interactors according to the BioGRID database. Red in-
actome database.
rs, defined by the number of peptides, score for the identification and intensity.
ed MV4-11 cells (E) and Kasumi-1 (F) cells followed by FUS detection.
unoprecipitates endogenous USP15 with and without MMC treatment.
P15 KO cells.
nuclear fractions after treatment with 4 nM bortezomib (BTZ) for 24 h. Cropped
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OPEN ACCESSUSP15 is, together with USP4 and USP11, part of a closely
related family of USPs (Nishi et al., 2014; Vlasschaert et al.,
2015; Wijnhoven et al., 2015). They are all expressed in hemato-
poietic early progenitors (Cabezas-Wallscheid et al., 2014;
Lancini et al., 2016), but only USP15 was linked to HSC activity
(Niederkorn et al., 2020). All three genes scored as hits in our
genetic screen and where found in complex in leukemia cells,
suggesting that they may cooperatively contribute to HSC ho-
meostasis. The potential biochemical interaction between
USP15 and USP11 and their specific and redundant roles in a
physiological setting support the rational design of allosteric de-
graders, which would have a stronger impact than individually
targeted small molecules. More broadly, our study calls for a
more systematic effort in understanding how DUBs regulate
normal and malignant HSC biology as a critical route toward
the selection of effective drug targets and targeted treatment
combinations.STAR+METHODS
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Naik, S.H., Perié, L., Swart, E., Gerlach, C., van Rooij, N., de Boer, R.J., and
Schumacher, T.N. (2013). Diverse and heritable lineage imprinting of early hae-
matopoietic progenitors. Nature 496, 229–232.
Naumann, M., Pal, A., Goswami, A., Lojewski, X., Japtok, J., Vehlow, A., Nau-
jock, M., G€unther, R., Jin, M., Stanslowsky, N., et al. (2018). Impaired DNA
damage response signaling by FUS-NLS mutations leads to neurodegenera-
tion and FUS aggregate formation. Nat. Commun. 9, 335.
Navarro, S., Meza, N.W., Quintana-Bustamante, O., Casado, J.A., Jacome, A.,
McAllister, K., Puerto, S., Surrallés, J., Segovia, J.C., and Bueren, J.A. (2006).
Hematopoietic dysfunction in a mouse model for Fanconi anemia group D1.
Mol. Ther. 14, 525–535.
Nestorowa, S., Hamey, F.K., Pijuan Sala, B., Diamanti, E., Shepherd, M., Lau-
renti, E., Wilson, N.K., Kent, D.G., and Göttgens, B. (2016). A single-cell reso-
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CD45.2-FITC Biolegend Cat#11-0454-82
Anti-phospho-Histone H2A.X (Ser139) Antibody, clone
JBW301
Millipore Cat#05-636-I; RRID:AB_2755003
Rabbit Polyclonal anti-53BP1 antibody Novus Biologicals Cat#NB100-304; RRID:AB_1659862
Mouse Monoclonal Anti-USP15 antibody Abcam Cat#ab56900
Rabbit Polyclonal Anti-USP15 antibody Abcam Cat#ab71713
Rabbit Polyclonal Anti-FUS antibody Novus Biologicals Cat# NB100-565
Alpha-Tubulin Mouse monoclonal antibody Sigma- Aldrich Cat#T90026
Goat anti-mouse HRP Life technologies Cat# 626520
Normal Rabbit IgG 2729S Cell Signaling Technology Cat#2729S
Alexa Fluor 568 goat anti–mouse Life Technologies Cat#A-11004
Alexa Fluor 488 goat anti–rabbit Life Technologies Cat#A-11008
Chemicals, Peptides, and Recombinant Proteins
Mitomycin C Santa Cruz Biotechnology, Inc. Cat# sc-3514
Topotecan Santa Cruz Biotechnology, Inc. Cat# sc-204919A
Resazurin Sodium Salt Sigma Cat# R7017
Bortezomid Biomol Cat#Cay10008822
Cisplatin solution Accord-Healthcare https://www.accord-healthcare.com/
Recombinant murine SCF PrepoTech Cat# 250-03
Recombinant murine TPO PrepoTech Cat# 315-14
Recombinant murine Flt3 ligand PrepoTech Cat#250-31L
(Continued on next page)
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Critical Commercial Assays
4D-Nucleofector Kit Lonza Cat# V4XP-3032
USP15 Gene Knockout Kit V2 (MV4-11 cells genome
editing, Figures 7H and 7I).
Synthego N/A
DNeasy Blood & Tissue Kit QIAGEN Cat# 69504
FuGENE HD Transfection Reagent Promega Cat# E2311
AlamarBlueTM Cell Viability reagent Thermo Fisher Scientific Cat#DAL1100
Streptavidin MicroBeads Miltenyi Bio- tec Cat#130-074-101
LS MACS Columns for magnetic cell isolation Miltenyi Bio- tec Cat# 130-042-401
AMPure XP solid-phase reversible immobilization kit
(SPRI)
Beckman Coulter Cat# A63881
Deposited Data
RNA sequencing data from K562 and KBM7 cells upon
USP15 knockdown by siRNAs
This paper GEO: GSE160524
RNA sequencing data from LSK cells from Usp15+/+
and Usp15/ mice
This paper GEO: GSE160525
RNA sequencing data from LSK cells and B cells from
Wild Type mice
Lancini et al., 2016 GEO: GSE58495
Mass spectrometry data, USP15 interactome This paper ProteomeXchange: PXD020612
CCLE DeMap v19q1 Broad Institute https://depmap.org/portal/download/
cBioPortal Cerami et al., 2012 https://www.cbioportal.org/
Cancer Cell Line Encyclopedia (CCLE) Broad Institute https://portals.broadinstitute.org/ccle
Database of hematopoietic cells in health and disease Hemaexplorer http://servers.binf.ku.dk/bloodspot/
Single Cell Expression Atlas Papatheodorou et al., 2020 https://www.ebi.ac.uk/gxa/sc/home
Experimental Models: Cell Lines
KBM7 chronic myelogenous leukemia (CML) cells Dr. Thijn R. Brummelkamp lab (NKI,
Amsterdam)
Blomen et al., 2015
K562 chronic myelogenous leukemia (CML) cells Dr. Thijn R. Brummelkamp lab (NKI,
Amsterdam)
Blomen et al., 2015
MV4-11 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
Kasumi 1 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
MONO-MAC 6 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
GDM-1 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
HL-60 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
GF-D8 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
THP-1 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
KG-1 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
KG-1A Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
ML-2 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
MONO-MAC-1 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
OCI-AML2 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
OCI-AML5 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
M-07e Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
EOL-1 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
PLB-985 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
SKNO-1 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
MOLM-13 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
PL-21 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
MOLM-14 Acute myeloid leukemia (AML) cells Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
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NB4 Dr. Saverio Minucci lab (IEO, Milan) Ravasio et al., 2020
Primary mouse Non-small Cell Lung Cancer (NSCLC)
KPE cells KrasG12D/+;Trp53/;EED/ genetic
background
Dr. Michela Serresi, Dr.
Gaetano Gargiulo (MDC, Berlin)
Serresi et al., 2016




Mouse: Usp15 knockout This paper MGI: Usp15 < em1Nki > ;
MGI:5810631; B6J-
Usp15 < em1Nki >
Mouse: C57BL/6J-Ly5.2 (C57BL/6J) Wild Type The Jackson Laboratory Stock No: 000664
Mouse: C57BL/6-Ly5.1 Wild Type The Jackson Laboratory Stock No: 002014
Oligonucleotides
Primer sequences for Illumina sequencing multiplexing
strategy: see Table S4
This paper N/A
Mouse Usp15 knockout: 50 CRISPR-guide (gRNA):
TCTTCTTCCACTAGCCGTAGCGG
This paper N/A
Mouse Usp15 knockout 30: CRISPR-guide (gRNA):
GTCACTTGATACGATAGCGCCGG
This paper N/A
Mouse Usp15: Forward: 50-
TCCAGTAGGAGTGAACCCGC-30
This paper N/A
Mouse Usp15: Reverse knockout allele: 50-
AGGTGGCTGAGAGTGAGAGCAGG-30
This paper N/A
Mouse Usp15, Reverse Wild type allele: 50-
GCCTTCCGCCATCTTCTTCCAC-30
This paper N/A
Human USP15 siRNAs: siGENOME Human USP15
(9958) siRNA-SMART pool
Dharmacon M-006066-01







Human sgRNA (sg01) targeting sequence: USP15ex3,
50-AAGGTGTTCCTTAAGTGACT-30 (U2OS cells






Human USP15, Pair of complementary DNA oligos:
USP15 Forward 50-
caccgAAGGTGTTCCTTAAGTGACT-30 (U2OS cells
genome editing; Figure S7).
This paper N/A
Human USP15, Pair of complementary DNA oligos:
USP15 Reverse 50-
aaacAGTCACTTAAGGAACACCTTc-30 (U2OS cells
genome editing; Figure S7).
This paper N/A
ASK-FN2 50-CGGCCTTTTTACGGTTCCTG-30 (U2OS
cells genome editing; Figure S7).
Addgene https://www.addgene.org/
53062/sequences/
TIDE analysis: Human genomic region surrounding
USP15 gRNA-targeted region: Forward 50-
GTTAGTGTTACAATTCTTCCAATACGG-30
This paper N/A
TIDE analysis: Human genomic region surrounding
USP15 gRNA-targeted region: Reverse,
50GTTTTATCAAAAACAGTGCAGCACAG-30
This paper N/A
TIDE analysis: Sanger sequencing Primer 50-
TTACAATTCTTCCAATACGGCCCAG-30
This paper N/A
(Continued on next page)
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qRT-PCR – mouse HPRT Forward: 50-
CTGGTGAAAGGACCTCTCG-30
This paper N/A
qRT-PCR - mouse HPRT Reverse: 50-
TGAAGTACTCATTATAGTCAAGGGCA-30
This paper N/A
qRT-PCR mouse Usp15 A Forward: 50-
TGTGGCTTAAGTAACTTGGGAAA-30
This paper N/A
qRT-PCR mouse Usp15 A Reverse: 50-
AAGTGGAGGTGTGTTGCTCA-30
This paper N/A
qRT-PCR mouse Usp15 B Forward: 50-
TCAGCTGGTACACACTGATGG-30
This paper N/A
qRT-PCR mouse Usp15 B Reverse: 50-
TGCTTTACAAACATACCCTGTTCT-30
This paper N/A
Primers used in Figures S6G and S6H for validation of
RNA-seq results are available upon request.
This paper N/A
Recombinant DNA
RNAi Consortium library (TRC Mm1.0) Sigma-Aldrich, MO MISSION TRC Mm1.0)
pLKO.1-puro Sigma-Aldrich, MO SHC001
pLKO.1-puro USP15sh15 Sigma-Aldrich, MO TRCN0000033215
pLKO.1-puro USP15sh16 Sigma-Aldrich, MO TRCN0000033216
pLKO.1-puro USP15sh17 Sigma-Aldrich, MO TRCN0000033217
pSpCas9(BB)-2A-GFP (PX458) plasmid Addgene Cat#48138
Plasmid: pLV[Exp]-Puro-H1/TO > hUSP15shRNA#1-
UBC > TetR(ns):T2A:EGFP
This paper N/A




TIDE software Dr. Bas van Steensel lab
(NKI, Amsterdam)
https://tide.nki.nl/
MaxQuant software package version 1.6.3.4 Max Planck Institute
of Biochemistry (Cox and
Mann, 2008)
https://www.maxquant.org
Reactome pathway analysis tool v3.7, database
release 73
Fabregat et al., 2017 https://reactome.org/
R v3.5 https://cran.r-project.org/ https://cran.r-project.org/
Progeny v1.6 Schubert et al., 2018 https://bioconductor.org/
packages/release/bioc/
html/progeny.html
Limma v3.36 Ritchie et al., 2015 https://bioconductor.
org/packages/release/
bioc/html/limma.html
ImageJ software (version:2.0) NIH; Dr. Bram van den
Broek (NKI, Amsterdam)
https://imagej.nih.gov/ij/
FACS data analysis FlowJo https://www.flowjo.com/
FlowJo Software
version 10.0.8r1. (Tree Star)





RNA-seq differential expression analysis R package R; DEGseq 10.18129/
B9.bioc.DEGseq
RNA-seq genecounts Itreecount https://github.com/NKI-
GCF/itreecount
(Continued on next page)
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Prism 7.0 GraphPad https://www.graphpad.
com/scientific-
software/prism/





X-ray irradiation Faxitron MultiRad 225 X-ray
irradiation system





Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead author Elisabetta
Citterio (elisabetta.citterio@gmail.com).
Materials Availability
Plasmid generated in this study and primers sequences are available upon request.
Data and Code Availability
The sequencing data discussed in this publication have been deposited in NCBI’s Gene Expression Omnibus (Edgar et al., 2002) and
are accessible through GEO Series accession numbers GSE160524
(https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE160524) and GSE160525 (https://www.ncbi.nlm.nih.gov/geo/query/
acc.cgi?acc=GSE160525).
The mass spectrometry proteomics data are available via ProteomeXchange with identifier PXD020612.
EXPERIMENTAL MODELS AND SUBJECT DETAILS
Mice: generation and breeding of USP15 knockout mice
This study utilized murine animal models, consisting of adult mice between 4 and 18 weeks of age. Age and sex matched mice were
used in experimental settings, as specified.
Full Usp15 knockout (KO) mice (MGI: Usp15 < em1Nki > ; MGI:5810631; B6J-Usp15 < em1Nki > ) were generated by CRISPR-
Cas9-mediated deletion of the Usp15 locus in C57BL/6J zygotes as described (Pritchard et al., 2017). Two CRISPR-guides (gRNAs)
were used that target Cas9 mediated double stranded DNA cleavage at both the 50 and 30 UTR ofUsp15. The sequence of the 50 and
30 targets were TCTTCTTCCACTAGCCGTAGCGG and GTCACTTGATACGATAGCGCCGG, respectively. The expected cleavage
sites (underlined) are 91.795 bp apart in the C57BL/6J genome (Figure S4A). Mice carrying a fullUsp15 knockout (KO) allele, in which
the 91 kb of cleavage site intermitting sequence is missing, were identified by PCR and sequence analysis. The Usp15 alleles were
detected with the following primers: forward, 50-TCCAGTAGGAGTGAACCCGC-30; reverse KO, 50-AGGTGGCTGAGAGTGAGAG-
CAGG-30; reverse wt, 50-GCCTTCCGCCATCTTCTTCCAC-30, yielding a product of 590 bp and 396 bp for Usp15-KO or Usp15
wt, respectively. The predicted CRISPR-Cas9-mediated fusion product for the Usp15-KO allele is: ccgcta.c.tatcgtat. The 590bp
Usp15-KO PCR fragment was sequenced, yielding the obtained fusion product: ccgtaTcGGatcgtat. Genotyping was performed
by PCR of genomic tail DNA using the Extract PCR kit (Bioline, cat. No. BIO-21127). All mice were kept on C57BL/6J (The Jackson
Laboratory) strain background (CD45.2+) in a specific pathogen-free environment. Usp15 mice were maintained heterozygous. All
animal experiments comply with Dutch and European regulations and ethical guidelines and have been authorized by our local exper-
imental animal committee at the Netherlands Cancer Institute (DEC-NKI). For determining survival, mice time to death was defined as
the latency between birth and unexpected death or a terminal disease stage indicated by > 20% weight loss or other symptoms of
severe sickness. Mice were sacrificed by CO2 asphyxiation and underwent necroscopy. Organs were collected and fixed for histo-
pathological analysis as described (Lancini et al., 2014).
Leukemia cells
KBM7 were grown in IMDM (GIBCO) medium. K562 were grown in RPMI 1640 (GIBCO) medium (Blomen et al., 2015). Culture me-
diumwas supplemented with 2mML-Glutamine (GIBCO 25030-164), 10% fetal calf serum (FCS, Thermo Scientific) 100 Uml1 peni-
cillin, and 100 mg ml1 streptomycin (Pen/Strep GIBCO 15140-163). Cells were incubated at 37C in a humidified atmosphere con-
taining 5% CO2.Cell Reports 33, 108533, December 29, 2020 e5
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OPEN ACCESSNB4, HL60, THP-1, ML-2, MV4-11, EOL-1, PLB-985, KASUMI were grown in RPMI 1640(GIBCO), 10% fetal bovine serum (South
American Origin, Thermofisher), 100 U ml1 penicillin, and 100 mg ml1 streptomycin (Pen/Strep GIBCO) 2mM of L-glutamine
(GIBCO)
GDM-1, GF-D8, MOLM-13, PL-21, MOLM-14 were grown in RPMI 1640 (GIBCO), 20% fetal bovine serum (South American Origin,
Thermofisher), 100 U ml1 penicillin, and 100 mg ml1 streptomycin (Pen/Strep GIBCO), 2mM of L-glutamine (GIBCO) (Ravasio
et al., 2020).
OCI-AML5 were grown in alpha-MEM (GIBCO), 20% fetal bovine serum (South American Origin, Thermofisher), 100 U ml1peni-
cillin, and 100 mg ml1 streptomycin (Pen/Strep GIBCO), 2mM of L-glutamine (GIBCO), 10 ng/ml GM-CSF
M-O7Ewere grown in in RPMI 1640 (GIBCO), 20% fetal bovine serum (South American Origin, Thermofisher), 100Uml1penicillin,
and 100 mg ml1 streptomycin (Pen/Strep GIBCO), 2mM of L-glutamine (GIBCO), 10 ng/ml GM-CSF
SKNO-1985 were grown in RPMI 1640(GIBCO), 10% fetal bovine serum (South American Origin, Thermofisher), 100 U ml1 peni-
cillin, and 100 mg ml1 streptomycin (Pen/Strep GIBCO) 2mM of L-glutamine (GIBCO)), 10 ng/ml GM-CSF
OCI-AML2 were grown in alpha-MEM (GIBCO), 20% fetal bovine serum (South American Origin, Thermofisher), 100 U ml1 peni-
cillin, and 100 mg ml1 streptomycin (Pen/Strep GIBCO), 2mM of L-glutamine (GIBCO)
KG1, KG- 1A were grown in RPMI 1640(GIBCO), 10% fetal bovine serum (South American Origin, Thermofisher), 100 Uml1 peni-
cillin, and 100 mg ml1 streptomycin (Pen/Strep GIBCO) 2mM of L-glutamine (GIBCO), 1mM Sodium Pyruvate (GIBCO) and HEPES
10 mM
Mono-Mac1 were grown in RPMI 1640(GIBCO), 10% fetal bovine serum (South American Origin, Thermofisher), 100 Uml1 peni-
cillin, and 100 mg ml1 streptomycin (Pen/Strep GIBCO) 2mM of L-glutamine (GIBCO), 1mM Sodium Pyruvate (GIBCO) and 0.1 mM
Non Essential Amino Acids (NEAA, GIBCO)
Mono-Mac6 were grown in RPMI 1640(GIBCO), 10% fetal bovine serum (South American Origin, Thermofisher), 100 Uml1 peni-
cillin, and 100 mg ml1 streptomycin (Pen/Strep GIBCO) 2mM of L-glutamine (GIBCO), 1mM Sodium Pyruvate (GIBCO) and 0.1 mM
Non Essential Amino Acids (NEAA, GIBCO) and 9 ug/ml Insulin.
KPE cell line
Primary mouse Non-small Cell Lung Cancer (NSCLC) KPE cells were isolated from KrasG12D/+;Trp53/;EED/ genetic back-
ground as described (Serresi et al., 2016). Cells were propagated in DMEM/F12medium supplemented with 10%FBS, and 5%peni-
cillin and streptomycin, 4ug/ml of hydrocortisone (Sigma), 5 ng/ml murine EGF (Invitrogen), Insulin-Transferrin-Seleniummix/solution
(GIBCO) and incubated at 37C in a 5% CO2%–95% air incubator.
U2OS cell line
U2OS osteosarcoma cells were grown in Dulbecco’s modified Eagle medium (DMEM; GIBCO), supplemented with 10% fetal calf
serum (FCS, Thermo Scientific), 100 Uml1 penicillin, and 100 mgml1 streptomycin (Pen/Strep GIBCO 15140-163). Cells were incu-
bated at 37C in a humidified atmosphere containing 5% CO2.
METHOD DETAILS
shRNA libraries
Lentiviral hairpins (pLKO.1) targeting annotated DUB genes(Mevissen and Komander, 2017) and controls were selected (Table S1).
Vectors were individually picked from glycerol stocks of The RNAi Consortium library (TRCMm1.0) (Sigma-Aldrich, MO), grown up on
agar plates and combined before maxiprep DNA isolation. Pooled plasmid libraries were used to produce lentiviral particles using
standard procedures (Gargiulo et al., 2014).
In vivo shRNA screens
Lineage negative (Lin-) hematopoietic stem and progenitors cells were isolated from the bone marrow (BM) of 8-10 weeks old wild-
type (wt) mice (C57BL/6J-Ly5.2)(CD45.2) and plated in serum-free medium supplemented with cytokines as described below.
Puromycin selection and MOI calculations were performed following our previously set up and validated protocol for in vivo RNAi
screens (Gargiulo et al., 2014). We adapted this protocol tomouse HSPC cells. Specifically, we first tested the sensitivity of HSPCs to
puromycin. We titrated puromycin in wild-type freshly isolated mouse lineage negative (lin-) cells in order to determine the optimal
concentration for selection, which we set at 1 mg/ml for 48 hours. This concentration was used for selection of Lin-cells infected
with the titered shRNA DUB libraries. Live cells were counted before and after puromycin selection using TC20 Automated cell
counter BIORAD and trypan blue.
Viral titer of the DUB shRNA libraries was first determined by serial dilution on 293T cells followed by 48 hours puromycin selection
(1 mg/ml) and Alamar blue cell viability assay. Freshly isolated Lin- cells were counted and a virus MOI < < 1 was calculated for the
infection (Gargiulo et al., 2014). Upon viral library infection (MOI < < 1) and puromycin selection we typically obtained 50%–80% live
transduced cells after 48 hours, while control un-transduced cells were visually distressed and trypan blue-positive.
Specifically for the screens, Lin- cells were pre-stimulated for 24 hours (hr) and transduced with pooled lentiviral shRNAs at low
multiplicity of infection (MOI < 0.5) using spin-inoculation at 1,800 rpm for 90 min at 32C. Twenty-four hours after infection, the cellse6 Cell Reports 33, 108533, December 29, 2020
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cells for DNA extraction of the INPUT(T0) sample. Next, 2x106 Lin- cells for the primary screening or 1x106 for the secondary screens
(representing a minimum of 3,500-fold enrichment over the library), were mixed with 1x106 freshly isolated BM cells from wt (C57BL/
6-Ly5.1)(CD45.1) mice and injected into recipient mice as described below. Recipient mice were sacrificed at 4 weeks post trans-
plantation (wpt) and femurs, tibia, and spleen were collected. Lin- cells from BM and CD43-, CD19+, CD220+, CD45.2 splenocytes
were purified as described below and genomic DNA was extracted for PCR amplification of the shRNAs.
PCR and next-generation sequencing
shRNAs sequences were retrieved from genomic DNA by PCR amplification as described (Gargiulo et al., 2014). For every sample, a
maximum of 8 mg genomic DNAwas divided over 4 50 mL PCR reactions using barcoded forward primers (PCR1). The products of all
reactions were pooled and a maximum of 1 mg from this PCR1 was used per reaction in subsequent PCR2 reactions using primers
containing Indexes for next-generation sequencing. Barcodes and Indexes for deep sequencing (Illumina HiSeq 2000) were incor-
porated into PCR primers as listed in Table S4.
PCR mixture per reaction: 10 mL HF Buffer (NEB), 1.25 mL 10-mM forward primer, 1.25 mL 10-mM reverse primer, 1.25 mL Phusion
Hot Start II polymerase (2U ml-1; Thermo Scientific, cat.n. F-530L), 1 mL 10-mM dNTPs, DMSO 3% (vol/vol), adding mQ and template
to 50 ml. PCR conditions were: 1’ @ 98C, 16 (PCR1) or 14 (PCR2) x (10 s @ 98C, 30 s @60C, 60 s @ 72C), 5 min @ 72C. PCR
products were purified using the AMPure XP solid-phase reversible immobilization kit (SPRI; Beckman Coulter, cat. no. A63881)
and subjected to Illumina next-generation sequencing. The shRNA sequence reads were aligned to the TRC library. Fold change
in individual hairpin representation in vivo was determined by comparing shRNA representation in each sample to that in the control
cell population remaining after tail vein injections during bone marrow transplantation (INPUT, T0). Each condition included in the
preliminary analysis was matched to its corresponding shRNA library removing those shRNA that weren’t present in any of the sam-
ples. Pairwise differential abundance analysis was performed between test sample and input using limma v3.36 (Ritchie et al., 2015)
after outlier removal using PCA. shRNA were considered as enriched or dropped out if logFC was higher than |1|, adj.Pvalue% 0.02
and avg. abundance > 2.5 . The analysis was done using R v3.5 programming language (https://cran.r-project.org/).
Bone marrow transplantation assays
For RNAi in vivo screens, puromycin selected, retroviral-transduced Lin- cells (CD45.2) were mixed with wt bone marrow cells
(CD45.1) as described above and injected into lethally irradiated (2 doses of 5.5 Gy TBI separated by an interval of 3 hours) wt
C57BL/6-CD45.1 recipient mice. Primary screen was performed with the full shRNA DUB library in five replicate mice. The DUB li-
brary was divided in two sub-pools, DUB1 and DUB2 sub-libraries, and two secondary screens were performed, DUB1 in four repli-
cate mice, DUB2 in 7 replicate mice.
Donor contribution was assessed based on the expression of CD45.1/CD45.2 antigens. At 4wpt primary recipients were sacrificed
and the frequency of donor-derived CD45.2 peripheral blood cells, splenocytes, Lin- and LSK were assayed by phenotypic profiling.
Lin- cells and CD45.2 splenic B cells for genomic DNA extraction and shRNA retrieval were isolated as described below.
In validation experiments, wt Lin- cells were transduced with individual lentiviral vectors and puromycin-selected as indicated
above. The percentage of LSK in the Usp15 wt (shCtrl) and knockdown (shUsp15) transduced, puromycin selected live cell popula-
tionwas assessed by phenotypic profiling beforemixingwith support wt BMcells. The difference in LSK between shCtrl and shUsp15
transduced cells before mixing and transplantation into recipient mice was corrected in order to transplant LSK equivalents.
1x106 lentiviral-transduced, puromycin resistant cells (CD45.2) were transplanted together with 1x106 total BM cells (CD45.1) into
lethally irradiated recipient mice (CD45.1). Recipient mice peripheral blood was monitored by FACS analysis at 2 wpt and every 4 wk
for 18 wk. Donor contribution and multilineage reconstitution were assessed based on the expression, respectively, of CD45.1/
CD45.2 antigens or CD19, CD3, and Gr1 markers in the CD45.2+ fraction. At 18 wpt, primary recipients were sacrificed and the fre-
quency of donor-derived CD45.2 B and T cells in the spleen and Lin-, LSK, HSC and myeloid progenitors in the bone marrow was
assayed by phenotypic profiling.
In competitive BM transplantation, BM was isolated from donor test animals (CD45.2, Usp15+/+ or Usp15/) and mixed in a 1:1
ratio with wt competitor cells (CD45.1)(8-10 weeks old mice). For each genotype and for the wt competitor BM, cells from 3 donors
and from 3 wt competitor mice were isolated and pooled before 1:1 mixing. Thereafter, 13 106 CD45.1/CD5.2 mixed BM cells were
transplanted into lethally irradiated CD45.1 recipient mice as described above. Flow cytometry staining for LSK and HSC of donors
was performed to ensure that the HSC frequency in test and control BM would be comparable. Differences in HSC were corrected
before transplantation to transplant stem cell equivalents. Chimerism in the blood of primary recipients and BM repopulation at 18
wpt were assessed as described above.
Mice were irradiated using FaxitronMultiRad 225 X-ray irradiation system. Irradiatedmice were treated with Enrobactin for the first
4 wk after irradiation. Immunophenotyping, Lin- isolation and CD45.2 splenocytes purification were performed as described below.
Flow cytometry
Peripheral blood was collected into EDTA-coated micro-tubes. For FACS analysis, blood was depleted from red blood cells by hy-
potonic lysis and staining was performed with fluorochrome-labeled antibodies, CD3-FITC, CD11b-PerCp/Cy5.5, CD19-APC, Gr1-
APC/Cy7.Cell Reports 33, 108533, December 29, 2020 e7
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by hypotonic lysis. For isolation of immature and of mature (resting) B cells, CD43 positive cells were first depleted using anti-mouse
CD43 (Ly-48) MicroBeads (MACS Miltenyi Biotec). Donor derived cells were then isolated by FACS sorting using fluorochrome-
labeled antibodies CD45.2-FITC, CD45.1-PE, CD19-APC, B220-Pb, CD43-biotin and Streptavidin APC/Cy7. For immunophenotyp-
ing of spleen upon transplantation, staining was performed with fluorochrome-labeled antibodies, CD3-FITC, CD8a-PerCp/Cy5.5,
CD4-APC, CD19-APCH7.
Analyses and cell sorting of hematopoietic precursors
To analyze Lin-, LSK, HSC, LKS-, CMP, GMP and MPP subpopulations (Cabezas-Wallscheid et al., 2014; Kiel et al., 2005; Oguro
et al., 2013; Wilson et al., 2008; Yeung and So, 2009), BM freshly isolated mononuclear cells (MNC) were first stained with Lineage
Cell Detection Cocktail-Biotinylated mouse antibody (MACSMiltenyi Biotec). For FACS analysis, cells were then directly stained with
fluorochrome-conjugated antibodies. We used 5 3 106 MNCs per staining. For quantifying LSK and HSC populations, cKit-APC,
Sca-1-PerCp/Cy5.5, CD48-FITC, CD150-PE/Cy7, CD135-PE and streptavidin-APC/Cy7 antibodies were used. For quantifying
LKS- progenitor populations, cKit-APC, Sca-1-PerCp/Cy5.5, CD34-FITC, CD16/32-PECy7, and streptavidin-APC/Cy7 antibodies
were used. For purifying Lin- cells for shRNA library viral infection or for culturing, depletion of lineage+ cells from MNCs was per-
formed using Biotin labeled Lin+ cocktail and Streptavidin MicroBeads (Macs; Miltenyi Bio- tec) and magnetic columns (Macs; Mil-
tenyi Biotec). For cell sorting of LSK, depletion of lineage+ cells was first performed as above before staining.
Cell cycle analysis of BM populations
Cell surface staining was performed as described above. Samples were then fixated in 3.7% Formaldehyde in PBS (Sigma)) for
30 min at RT. Cells were permeabilised in PBS/BSA(1%)/Tween20 (0.025%)(PBT) for 15min at RT and harvested in PBT containing
10 mg/mL DAPI for chromatin labeling. Cell cycle analysis was performed as described (Pilzecker et al., 2017).
Assessing Cleaved Caspase-3 levels of BM populations
Cell surface staining, fixation and permeabilization was performed as described above followed by staining with CleavedCaspase-3-
AF488 antibody for 30min at RT in PBT. Cells were washed twice with PBT and harvested in PBT containing 10 mg/mL DAPI for chro-
matin labeling.
All FACSmeasurements were performed with a BD LSRFortessa cell analyzer (BD Biosciences). Cell sorting was performed with a
FACSAria (BD). All FACS data were analyzed using FlowJo Software version 10.0.8r1. (Tree Star).
Hematopoietic stem and progenitor cells liquid culture, time-lapse imaging and proliferation assays
Mice were sacrificed at the indicated age (8-12 weeks). Lineage negative (Lin-) isolation, LSK FACS sorting and cell surface staining
was performed as described above. Cells were plated on Ultra-Low Attachment multiwell plates (CorningCostar) in StemPan
SFEM (StemSpan Serum-Free Expansion Medium (SFEM) STEMCELL Technologies) supplemented with mouse SCF 100 ng/ml,
mouse thrombopoietin (mTpo) 50 ng/ml and mFlt3 ligand 50 ng/ml (PrepoTech) (Ye et al., 2008). Medium was replenished and cells
were expanded in 3% oxygen to maintain optimal growth. To evaluate proliferation, 1,000 Lin- cells were plated in 96-well plates at
day 7 of culture. 4 wells per conditions were imaged (phase-contrast) with a 4 hr interval for 6.5 d using the IncuCyte FRL (Essen
BioScience). Confluence was determined by the IncuCyte software, based on area (confluence) metrics. Plating of 500 cells/well
gave similar results. FACS sorted LSK cells from individual animals were grown individually. LSK were plated at day 8 of culture
and monitored for growth by counting live cells by Trypan blue exclusion using a TC20TM Automated Cell Couter (BIORAD) at the
indicated time. Four wells per condition were counted.
CFU-C colony-forming assay
BMMNCs cells were seeded on 35-mm culture dishes in triplicate in methylcellulose medium supplemented with cytokines (Metho-
Cult GF M3434, STEMCELL Technologies). CFU-Cs (colony forming units in culture) include CFU-GEMM (granulocyte, erythroid,
macrophage, megakaryocyte), multipotential progenitors and lineage-restricted progenitors of the erythroid (BFU-E, burst-forming
unit–erythroid), and granulocytic, monocyte- macrophage (CFU-GM). Cultures were incubated at 37C under 5% CO2. Colonies
were quantified at day 8.
Leukemia cells RNA interference and cell viability assays
USP15 siRNAs (siGENOMEHumanUSP15 (9958) siRNA-SMART pool M-006066-01) and control (Ctrl) siRNAs (siGENOMENon-Tar-
geting siRNA Control Pool#2 D-001206-14-05) were from Dharmacon. Cells were transfected using Lipofectamine RNAiMAX Re-
agent from Life Technologies following the manufacturer’s instructions and assayed at 72 hr after transfection in western blotting,
viability assays and immunofluorescence or RNA-seq.
For inducible USP15 knockdown experiments, we have tested 4 shRNAs. To rule out potential off-target effects by one shRNA, we
used two different shRNAs for experiments in Figures 6I and 6K: human USP15 shRNA#1 ‘TAAACCAGCATCCTGAATGG’ and
shRNA#2 ‘TTTCATGAACTCAGCTATTC’, respectively. The additional shRNA tested were: ‘GCATTAGGCTGCCGTATATA’, and
‘CGCTTATAAGAACTATGATT’ and these were found insufficiently potent on-target. The shRNA-containing bicistronic vectorse8 Cell Reports 33, 108533, December 29, 2020
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repressor-T2A-eGFP for FACS sorting of TetR positive cells.
Viability assayswere performed using AlamarBlueTMCell Viability reagent (Thermo Fisher Scientific). Relative viability was normal-
ized to the control siRNA transfected cells and corrected for back-ground signal.
TCGA pan-cancer gene expression analysis and Single Cell Expression analysis
Gene expression analysis by RNaseq was compiled using data from all TCGA cohorts (Cerami et al., 2012). Gene expression was
measured using the IlluminaHiSeq technology. Data from all TCGA cohorts are combined to produce this dataset. Values are PAN-
CAN expression unit - (log(norm(exp) + 1)) transformed RSEM values. Single Cell Expression analysis for USP15was performed using
data from the Single Cell Expression Atlas (Papatheodorou et al., 2020) (https://www.ebi.ac.uk/gxa/sc/home).
RNA-seq gene expression analysis
For gene expression analysis, KBM7 or K562 cells were transfected with USP15 or control siRNAs as described above. Total RNA
was extracted at 72 h after transfection. For LSKs, cells were FACS sorted from freshly isolated BM and total RNA was extracted. n =
3 Usp15+/+ and n = 2 Usp15/ littermates (2 months old). Samples were prepared using TruSeq protocols, and standard sample
preparation protocols and RNA-seq was performed on a Hiseq2000 machine (Illumina) at the NKI Genomics Core Facility.
The sequencing data have been deposited in NCBI’s Gene Expression Omnibus (Edgar et al., 2002) and are accessible through
GEO Series accession numbers GSE160524 and GSE160525.
Sensitivity assays
Cells were cultured in the proper culture medium with doxycycline for 5 days (100ng/ml) to induce USP15 knockdown. Cells were
then seeded in 384 well plates 24 hr before treatment. For IR, cells were irradiated with the indicated dose and cell viability was as-
sessed 3 days after IR using a medical irradiator platform (XenX). Similar data were obtained with siUSP15. To determine the 30nM
MMC concentration, MMC dose-response experiments were previously assessed and 30nM was determined as the IC50 dose for
MV4-11 cells in our experimental conditions. Cell viability was assessed at 72 hours. Doxycycline and drug were refreshed daily.
In vivo cisplatin (CsPt) Sensitivity Assay. Mice were injected i.v. with 0.8 mg/kg cisplatin, a relative low dose (Pilzecker et al., 2017),
or PBS. After 2 d, the BM was isolated and analyzed as described above.
Immunofluorescence and quantitative image analysis
In vitro cultured murine LSK or human K562 and KBM7 cells were deposited on charged slides (Superfrost Plus; Menzel-Glaser)
by cytospin and directly fixed in 4% paraformaldehyde. Immunostaining with antibodies against 53BP1 was performed as pre-
viously described (Lancini et al., 2014). Counterstain was with Alexa Fluor 488–conjugated secondary antibodies and DAPI
(200 ng/ml) (Sigma-Aldrich). Micronuclei were scored on fixed cells stained with DAPI. Digital images were acquired using a
microscope (AxioObserver Z1; Carl Zeiss) with an ORCA-ER CCD charge-coupled device) camera (C4742-80-12AG; Hama-
matsu) and Zen software (40x and 63x magnification). A macro in ImageJ software (version:2.0) (developed by Bram van
den Broek, NKI, Amsterdam) was used for quantification of spontaneous 53BP1 DNA damage foci. The DAPI channel was
used to select the nuclei of the cells in the field. Briefly, Z stacks are converted to two dimensional via one of several user-
defined methods: maximum intensity projection, automatically select sharpest slice or manually select a slice. Region of inter-
ests (ROIs) of candidate nuclei are then automatically obtained throughout the image stack by auto-thresholding an outlier-
removed median-filtered (0.7 mm radius) z projection of the nuclei channel, followed by a watershed command to separate
touching nuclei and particle analyzer run with size (> 4 and 40 mm2), and circularity (> 0.25) constraints. In the detection of
53BP1 foci, the foci threshold level is defined by the signal-to-noise ratio (SNR): a (user-set) factor times the s.d. of the
background fluorescence intensity of the nucleus. The latter property is approximated by first crudely removing signal outliers
(the foci), and then taking the median and s.d. of the lower approximate 80% pixel values in the ROI, respectively. The
background intensity is subtracted using a Difference of Gaussians filter. Foci are then identified as regions of adjacent pixels
with gray values, exceeding the SNR threshold and area larger than a certain minimum. In the procedure, the SNR is the
only user-defined parameter, and is iteratively optimized by comparing the detected foci with the original signal in an overlay
image.
Protein analysis
Cell were lysed with RIPA buffer (10 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1% Triton X-100, 0.1% sodium deoxycholate, 0.1% SDS,
140 mM NaCl, 1 mM PMSF) containing protease inhibitor cocktail (Complete, Roche) and phosphatase inhibitors 9Na Fluoride
10mM final concentration, Na orthovanadate 1 mM final concentration and NaPPi 1 mM final concentration) and whole cell extract
was loaded on SDS-PAGE onNuPAGE gels, followed by western blotting with the indicated antibodies (Table S4). Filter blocking and
antibody incubation were performed in PBS supplemented with 0.1(v/v) % Tween and 5%(w/v) bovine milk powder.
For validation of shRNAs, wild-type mouse Non-small Cell Lung Cancer (NSCLC) KPE cells (Serresi et al., 2016) were transduced
with individual lentiviral vectors and puromycin-selected for 48hrs as indicated above, followed by protein extraction and immunoblot
analysis.Cell Reports 33, 108533, December 29, 2020 e9
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Total RNA was extracted using TRIZOL reagent (Life Technologies) or ReliaPrepTM RNAminiprep System (Promega) and cDNA was
prepared using Superscript II RT and oligo(dT)n primers (Life technologies). qRT-PCR was performed on a StepOnePlusRT-PCRsys-
tem(AppliedBiosystems) usingSYBR Green PCR Master Mix (Applied Biosystems). The amount of target, normalized to an endog-
enous reference (HPRT), was calculated by 2-DDCT. Primer sequences were as follows: mHprt forward, 50-CTGGTGAAAG-
GACCTCTCG-30; mHprt reverse, 50-TGAAGTACTCATTATAGTCAAGGGCA-30; two different pairs of USP15 primers were used,
mUsp15 A forward, 50- TGTGGCTTAAGTAACTTGGGAAA-30; mUsp15 A reverse, 50-AAGTGGAGGTGTGTTGCTCA-30; mUsp15 B
forward, 50-TCAGCTGGTACACACTGATGG-30; mUsp15 B reverse, 50-TGCTTTACAAACATACCCTGTTCT-30. Primers used in Fig-
ure S6G,H for validation of RNA-seq results are available upon request.
Antibodies
Antibody specifications are listed in Tables S5 and S6.
U2OS cells genome editing: sgRNA design and cloning
sgRNA sequences targeting human USP15 were selected from the Human Brunello CRISPR knockout pooled library (Doench et al.,
2016) (Addgene #73178) and further selected on the basis of high quality score in two additional online tools: CRISPRDesign (https://
zlab.bio/guide-design-resources) and CRISPRscan (https://www.crisprscan.org/). The following sgRNA (sg01) targeting exon 3 of
USP15 DUSP domain was used in this study: USP15ex3, 50-AAGGTGTTCCTTAAGTGACT-30. Pairs of complementary DNA oligos
(forward: 50-caccgAAGGTGTTCCTTAAGTGACT-30; reverse: 50-aaacAGTCACTTAAGGAACACCTTc-30) were annealed and the
DNA oligonucleotide duplex was cloned in the Bbs1 restriction site of pSpCas9(BB)-2A-GFP (PX458) plasmid (Plasmid #48138,
Addgene). sgRNA sequence was verified by DNA Sanger sequencing using the following primer: ASK-FN2 50-
CGGCCTTTTTACGGTTCCTG-30.
Transfection and fluorescence activated cell sorting (FACS)
Plasmids were transfected into U2OS cells using FuGENE HD Transfection Reagent (Promega), according to the manufacture’s
instructions. After 48 hours in culture, cells were trypsinized, washed with PBS, and resuspended in PBS (supplemented with 3%
BSA) and passed through a cell strainer (Falcon Round-Bottom Tubes with Cell Strainer Cap, Catalog #38030). Cells were individ-
ually sorted (BD FACSAria, BD FACS Diva 8.0.1 sofware) based on EGFP signal into tissue culture 96-well plates (CELLSTAR-
Greiner) at a single cell per well for clonal expansion. Viable individual clones were then transferred to 24 well plates for clonal expan-
sion and screening.
MV4-11 cells genome editing and electroporation
Genome editing of MV4-11 cell lines described in the work was performed by electroporation using Amaxa 4D-Nucleofector Kit
accordingly to the manufacturer’s instructions. Briefly 2x105 cells were counted and resuspended in SF buffer and supplement
and electroporate with the program CM137. To knock out h-USP15 was used Synthego Gene Knockout Kit V2 following the man-
ufacturer’s instructions.
Genomic DNA extraction, PCR and Sanger sequencing and TIDE analysis
Genomic DNAwas extracted using DNeasy Blood & Tissue Kit (QIAGEN). The human genomic region surrounding USP15 gRNA-tar-
geted sequence was amplified using the following primers: forward, 50- GTTAGTGTTACAATTCTTCCAATACGG-30; reverse,50GTTT-
TATCAAAAACAGTGCAGCACAG-30. PCR was performed using Thermo Scientific Phusion High-Fidelity DNA polymerase in GC
buffer. PCR conditions were as follows: 30 s at 95C, followed by 25 cycles of 30 s at 95C, 30 s at 64C, and 30 s at 72C, followed
by 3 min at 72C. Primer 50-TTACAATTCTTCCAATACGGCCCAG-30 was used for Sanger sequencing. About 100-200 ng DNA from
purified PCR samples was prepared for sequencing using BigDye terminator v3.1. Samples were analyzed by an Applied Bio- sys-
tems 3730x1DNAAnalyzer. The data obtainedwas analyzed using the TIDE software (https://tide.nki.nl). The decomposition window
used for TIDE was set to indels of size 0-10 bp, p threshold of 0.001.
Sample preparation for mass spectrometry
For label-free proteomics analysis, samples were subjected to tryptic on-bead digest as described in Hubner et al. Briefly,
washed beads were taken up in digestion buffer (2 M urea buffer / 50 mM Tris pH 7.0 / 1 mM DTT / 5 mg/mL trypsin) and
pre-digested for one hour. The supernatant was subjected to reduction (4 mM DTT for 30 min), alkylation (10 mM iodoacetamide
for 45 min) and further over-night digest with 0.5 mg trypsin. After desalting, samples were measured by LC-MS/MS on an Orbi-
trap Exploris 480 mass spectrometer (Thermo) connected to an EASY-nLC system (Thermo). A volume of 2 ml was injected and
a 45 min gradient (5 to 55% acetonitrile) was applied. The peptides were separated on an in-house prepared nano-LC column
(0.074 mm x 250 mm, 3 mm Reprosil C18, Dr Maisch GmbH) using a flow rate of 250 nL/min. MS acquisition was operated at an
MS1 resolution of 60,000 and a scan range from 350 to 1800 m/z. For data-dependent MS2 acquisition a cycle time of 1 s was
used and precursors were selected for fragmentation in data-dependent mode using an MS2 resolution of 15,000, a maximum




For analysis the MaxQuant software package version 1.6.3.4 (Cox and Mann, 2008) was used. Carbamidomethylation on cysteine
was set as a fixed modification and oxidized methionine, acetylated N-termini and deamidation on asparagine as well as glutamine
were used as variable modifications. An FDR of 0.01 was applied for peptides and proteins and database search was performed us-
ing a mouse Uniprot database (July 2018).
The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE (Perez-Riverol
et al., 2019) partner repository with the dataset identifier PXD020612.
MS intensities were normalized by the LFQ algorithm while using the match-between-runs feature and separating the cell lines in
parameter groups for individual LFQ normalization. Further data analysis was done using R. A number of at least two peptides per
protein and three valid values in the USP15 group was required. The resulting list was imputed using a column-wise Gaussian dis-
tribution, a width of 0.2 and a downshift of 1.8. Log2-transformed LFQ-intensities among the replicates of the groups to be related
were taken for comparison by applying a moderated t test. Proteins with a Benjamini-Hochberg-adjusted p value smaller than 0.1
(i.e., 10% FDR) were considered as significantly enriched (Cox and Mann, 2008; Hubner et al., 2010). From the interactors, proteins
with a p-adjusted value < 0.05 compared to IgG, for each condition, were taked into account. The 38 USP15 interactors were
analyzed by using Reactome pathway analysis tool (Reactome.org; Pathway browser v3.7, database release 73; https://
reactome.org/) (Fabregat et al., 2017).
Immunoprecipitation
For immunoprecipitation previous to mass spectrometry, cells were washed twice in PBS and lysed in RIPA buffer buffer (Thermo
Fisher) supplemented with complete EDTA-free protease inhibitor cocktail (Sigma), 1mM Na3VO4, 10mM NaF, 1mM Sodium pyro-
phosphate and 1mMNEM. For validation immunoprecipitation 0.1% Igepal lysis buffer (150mMNaCl, 20mMTris pH 7.5, 0.5mMEth-
ylenediaminetetraacetic acid (EDTA) supplemented with protease and phosphatase inhibitors) was used. Lysates were sonicated in
water bath Bioruptor 30 s on/off for 5 cycles and after clearing the lysate by centrifugation, input was taken. USP15 ab71713, FUS or
IgG (2.5 ug/mg) antibodies were added and incubated overnight at 4C in rotation. For precipitation of immunocomplexes, protein A
Dynabeads (Thermofisher) were added and incubated for 3h at 4C in rotation. After extensive washing immunoprecipitates were
kept on beads for digestion (Mass spectrometry) or eluted by boiling at 95C for 5min with SB4x before analysis by SDS-PAGE.
Cellular fractionation
Cells were harvested and washed twice in PBS, lysed in buffer A (10 mM HEPES pH 7.9, 1.5mM MgCl2, 10mM KCl, 0.2% Igepal,
1mM DTT, complete EDTA-free protease inhibitor cocktail (Sigma), 1mM Na3VO4, 10mM NaF and 1mM NEM); incubated 5min
on ice and spin down at 1600xg 5min to extract cytoplasmatic andmembrane proteins. The pellet, containing the nuclei, waswashed
once with buffer A, centrifuged again for 10min and lysed in RIPA buffer (Thermo Fisher) supplemented with protease and phospha-
tase inhibitors indicated above. Lysates were sonicated in water bath Bioruptor 30 s on/off for 5 cycles and centrifuged for 30min at
13000rpm; the supernatant contained nuclear extract was transferred to a fresh tube. Both extracts were boiled at 95C for 5min with
SB4x.
QUANTIFICATION AND STATISTICAL ANALYSIS
Statistical analysis was performed in GraphPad Prism 7.0, using an unpaired two-tailed Student’s t test or Multiple t test were spec-
ified. Animal survival experiments were analyzed with a Log-rank nonparametric test and expressed as Kaplan-Meier survival curves.
In all Figures: *, p < 0.05; **, p < 0.01; ***, p < 0.001; ****, p < 0.0001.Cell Reports 33, 108533, December 29, 2020 e11
